<DOC>
	<DOC>NCT01249118</DOC>
	<brief_summary>The primary objective of Part 1 of this study is to evaluate the safety and tolerability of the intravenous (IV) dose of GDC-0973. The primary objectives of Part 2 of this study are to evaluate the absolute bioavailability of GDC-0973 and to evaluate the pharmacokinetic (PK) of GDC-0973 following IV and oral administration. The secondary objective of Part 2 of this study is to evaluate the safety of GDC-0973 administered orally and intravenously.</brief_summary>
	<brief_title>An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Within body mass index range 18.5 to 29.9 kilograms per square meter (kg/m^2) In good health, determined by no clinically significant findings from medical history, 12lead electrocardiogram (ECG), and vital signs Clinical laboratory evaluations within the reference range for the test laboratory Negative test for selected drugs of abuse at Screening and at each Checkin Negative hepatitis panel and antihepatitis C virus and negative human immunodeficiency virus (HIV) antibody screens Healthy males and females of nonchildbearing potential or who agree to use effective contraception Exclusion Criteria Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy, hernia repair, and cholecystectomy will be allowed History or presence of an abnormal ECG History of alcoholism or drug addiction prior to period 1 checkin Use of any tobaccocontaining or nicotinecontaining products prior to period 1 checkin Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 28 days or 5 halflives, whichever is longer, prior to period 1 checkin Use of any prescription medications/products, including proton pump inhibitors, within 14 days prior to period 1 checkin Poor peripheral venous access Any acute or chronic condition that would limit the participants ability to complete and/or participate in this clinical study Female participant is pregnant, lactating, or breastfeeding Predisposing factors to retinal vein occlusion (RVO)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>